Clinical trial · Interventional
DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections
Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Results of 5 first patients show that chips' cauterization interferes the signal
Summary
Brief summary (as posted)
The aim of this study is divided in 4 different steps: * the first step has two different purpose: assess the impact of the storage medium of fresh prostatic chips on fluorescence signal and adjust the entire chain (immunolabelling,counter-stain and imaging), * the second step is the adaptation of immunolabelling protocol on histopathology slides, using fresh prostatic tissue, * the third step is to validate the use of: 1. the medical device created by the FEMTO-ST institute use for the detection of fluorescence signal on fresh tissue, 2. the Light-CT scanner use for tissue structural observation. * the four step is to check the preservation of morphological structure of tissue under the effect of laser excitation from the medical device.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trans-urethral resection | Procedure | — | UNRESOLVED |
| Use of the FEMTO-ST institute medical device | Device | — | UNRESOLVED |
| Use of the Light-CT scanner | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Fluorescence assesment
- description
- All patients undergo a transurethral resection. There are four different steps in the study: * the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain, * the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol, * the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device, * the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner.
- interventionNames
- Procedure: Trans-urethral resection
- Device: Use of the FEMTO-ST institute medical device
- Device: Use of the Light-CT scanner
Primary outcomes (1)
- measure
- Complete fluorescence measurement over each field of vision.
- timeFrame
- 1 day
- description
- Determinate for the anti-PSMA antibody with Alexa Fluor 488 tracer, the ideal couple of antibody concentration/incubation time giving the highest immunofluorescent signal in the adjustment of fixed tissue sample protocol to fresh tissue sample protocol.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male patient over 18 years old. * Patient scheduled for trans-urethral resection of prostate with: 1. prostate specific antigen (PSA) blood level ≤ 4 ng/ml and age \> 80 years old 2. a suspected prostate cancer after a digital rectal examination (DRE) and a PSA blood level \> 50 ng/ml or an existing prostate cancer * Patient affiliated to social security or beneficiary of such a regime. Exclusion Criteria: * Protected patient referred to in Articles L1121-6 to L1121-8 of the Code of Public Health
References
Publications (0)
Data not yet available